Transthyretin Amyloidosis Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Type (ATTR-PN, ATTR-CM), By Therapy (Targeted Therapy (Onpattro, Inotersen, Vyndaqel/Vyndamax), Supportive Therapy, Pipeline Therapy), By Disease Type (Hereditary Transthyretin Amyloidosis (Polyneuropathy, Cardiomyopathy, Mixed Type), Wild Type Amyloidosis), By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, Online Pharmacies), By Region, By Competition

  • Industry : Healthcare
  • Pages : NA
  • Published Date : NA
Customization Enquiry

Buy Now

Summary

Report Description

Forecast Period

2024-2028

Market Size (2022)

USD 4.95 Billion

CAGR (2023-2028)

7.26%

Fastest Growing Segment

Hereditary Transthyretin Amyloidosis

Largest Market

North America

 

Market Overview

Global Transthyretin Amyloidosis Treatment Market has valued at USD 4.95 Billion in 2022 and is anticipated to project robust growth in the forecast period with a CAGR of 7.26% through 2028. The growth is attributed to the extensive research in the development of new therapies and the presence of robust pipeline drugs that are used to treat transthyretin. It is a rare and progressive disease characterized by the deposition of abnormal proteins such as misTTR in organs and tissue of the body. The symptoms associated with the disease mainly depend on the organs that are involved such as carpel syndrome for arms, lumbar spinal stenosis for the back, vitreous opacities for the head and neck, and swelling at the feet. There are two major types of transthyretin amyloidosis such as mutated/ hereditary ATTR and wild-type ATTR. It often affects major organs of the body such as the liver, kidney, nerves, and heart. However, the unavailability of advanced diagnostic facilities in developing countries is a major challenge to the transthyretin amyloidosis treatment market growth.

Key Market Drivers

Increasing Disease Awareness

The growth of the Global Transthyretin Amyloidosis Treatment Market is intricately linked to the strategic enhancement of disease awareness. As awareness increases, there is a simultaneous uptick in early diagnosis and treatment initiation. This, in turn, fosters a higher demand for therapeutic interventions, propelling market expansion. Elevated disease awareness serves as a catalyst for patient and healthcare provider education, facilitating informed decision-making regarding available treatment options. This heightened awareness not only reduces diagnostic lag but also fuels a proactive approach towards managing transthyretin amyloidosis. Pharmaceutical companies, recognizing this trend, can capitalize on the growing market by investing in targeted marketing campaigns and educational initiatives. Moreover, a well-informed patient population is more likely to actively seek medical assistance, leading to an augmented patient pool for treatment interventions. The resultant surge in demand not only bolsters the market's revenue but also stimulates research and development efforts to innovate novel therapeutic solutions. In essence, the symbiotic relationship between increasing disease awareness, early diagnosis, and heightened demand for treatment modalities forms the cornerstone for the sustained growth of the Global Transthyretin Amyloidosis Treatment Market.

Advancements in Diagnostic Technologies

The growth trajectory of the Global Transthyretin Amyloidosis Treatment Market is poised to ascend with the integration of cutting-edge diagnostic technologies. Advancements in diagnostic tools not only facilitate swift and accurate disease identification but also enable a more nuanced understanding of individual patient profiles. This precision in diagnosis is instrumental in tailoring targeted treatment strategies, thereby propelling the demand for specialized therapeutics. Sophisticated diagnostic technologies, such as genetic testing and biomarker identification, empower healthcare professionals to identify transthyretin amyloidosis at earlier stages, fostering timely intervention. Early detection, in turn, correlates with improved treatment outcomes and patient prognosis. This positive correlation incentivizes both healthcare providers and patients to adopt these advanced diagnostic tools, creating a conducive environment for market expansion. Furthermore, the integration of innovative diagnostic technologies stimulates research and development initiatives, driving continuous improvement in treatment modalities. Pharmaceutical companies, in response to evolving diagnostic capabilities, are incentivized to invest in novel therapies, creating a cycle of innovation that contributes to the overall growth of the market. In essence, the synergy between diagnostic advancements and therapeutic interventions forms a pivotal driver for the Global Transthyretin Amyloidosis Treatment Market.

Patient Advocacy and Support Groups

The growth of the Global Transthyretin Amyloidosis Treatment Market is significantly influenced by the pivotal role played by patient advocacy and support groups. These groups serve as catalysts for heightened disease awareness, patient education, and community engagement. By fostering a sense of community among individuals affected by transthyretin amyloidosis, these advocacy groups create a platform for shared experiences and information exchange. Patient advocacy groups contribute to market growth by actively participating in awareness campaigns, encouraging early diagnosis, and promoting treatment options. Their influence extends to shaping healthcare policies and driving research initiatives, thereby creating an environment conducive to the development and adoption of innovative therapies. Moreover, the collaboration between patient advocacy groups and pharmaceutical companies enhances the development and accessibility of treatment options. By incorporating patient perspectives, these collaborations ensure that therapeutic solutions align with the needs and preferences of the affected community. This not only aids in the market penetration of treatments but also cultivates a supportive ecosystem that encourages patient adherence and long-term engagement with healthcare services. In essence, the symbiotic relationship between patient advocacy and the Global Transthyretin Amyloidosis Treatment Market underscores the significance of a united front in driving awareness, research, and ultimately, the overall growth of the market.


Download Sample Report

Key Market Challenges

Limited Treatment Options

The growth of the Global Transthyretin Amyloidosis Treatment Market faces a substantial hindrance due to the challenge of limited treatment options. The scarcity of diverse therapeutic interventions constrains the market's potential for expansion, as it narrows the choices available for both healthcare providers and patients. This constraint not only limits the ability to address the varied needs of individuals but also hampers the overall efficacy of managing transthyretin amyloidosis. The lack of treatment diversity poses a barrier to market growth by reducing competitive dynamics among pharmaceutical companies. A dearth of alternative therapies may result in limited innovation and slower development of new treatment modalities. Additionally, it heightens the risk of treatment resistance and suboptimal outcomes for patients, impacting their confidence in available therapeutic solutions. Moreover, from a business perspective, the constrained treatment landscape diminishes the revenue potential for pharmaceutical companies operating in this market. The competitive edge that a diverse product portfolio provides is compromised, impacting market share and profitability.

Diagnosis Challenges

The growth trajectory of the Global Transthyretin Amyloidosis Treatment Market faces impediments due to the substantial challenges associated with diagnosis. The intricate nature of transthyretin amyloidosis often leads to delayed or inaccurate diagnoses, hindering timely intervention and treatment initiation. The complexity of symptoms and the overlap with other medical conditions pose challenges for healthcare professionals, resulting in a diagnostic lag that impacts patient outcomes. Diagnostic challenges contribute to a cascade of issues for the market. Firstly, delayed diagnosis limits the patient pool seeking treatment, restricting market demand. Secondly, the lack of standardized diagnostic protocols hampers the efficiency of clinical trials and research initiatives, impeding the development of new treatment modalities. Additionally, the uncertainty associated with accurate diagnosis may lead to suboptimal treatment choices, affecting patient satisfaction and long-term engagement with therapeutic interventions. From a business perspective, the diagnostic hurdles create a barrier for pharmaceutical companies aiming to position their treatments effectively in the market. The market's potential for growth is constrained by the critical need for streamlined, accurate diagnostic tools that facilitate early and precise identification of transthyretin amyloidosis. Addressing these diagnostic challenges is pivotal for unlocking the full growth potential of the Global Transthyretin Amyloidosis Treatment Market.

Key Market Trends

Advancements in Gene Therapies

The growth trajectory of the Global Transthyretin Amyloidosis Treatment Market is poised for acceleration with the advent of groundbreaking advancements in gene therapies. Innovations in gene-based interventions hold immense promise for revolutionizing the treatment landscape of transthyretin amyloidosis. Gene therapies have the potential to address the root cause of the disease at a molecular level, providing a paradigm shift towards more targeted and efficacious treatment options. The development of gene therapies not only enhances the therapeutic arsenal but also attracts substantial investment and research interest, fostering a competitive market environment. These advancements open new avenues for pharmaceutical companies to differentiate their offerings and tap into a rapidly expanding market segment. Furthermore, gene therapies showcase the potential to provide durable and transformative outcomes for patients, creating a compelling value proposition for both healthcare providers and individuals affected by transthyretin amyloidosis. The growing focus on precision medicine and personalized treatment approaches aligns with the inherent capabilities of gene therapies, driving increased adoption and market penetration. In essence, the integration of advanced gene therapies stands as a key driver propelling the growth of the Global Transthyretin Amyloidosis Treatment Market, heralding a new era of targeted and innovative solutions for this complex and challenging medical condition.

Targeted Therapies and RNA Interference

The Global Transthyretin Amyloidosis Treatment Market is poised for dynamic growth fueled by the emergence of targeted therapies and RNA interference (RNAi) technologies. Targeted therapies, designed to specifically address the underlying mechanisms of transthyretin amyloidosis, offer a more precise and effective treatment approach. This focus on the root cause enhances therapeutic outcomes, reducing side effects and improving overall patient satisfaction. RNA interference, a revolutionary technology that enables the selective silencing of disease-causing genes, holds immense promise for transthyretin amyloidosis. By suppressing the production of aberrant transthyretin protein, RNAi therapies have the potential to halt disease progression at the molecular level. This innovative approach not only diversifies the treatment landscape but also positions the market for significant expansion. The strategic integration of targeted therapies and RNA interference aligns with the industry's trend toward personalized medicine, catering to the unique genetic and molecular profiles of individual patients. As pharmaceutical companies invest in research and development to bring these advanced therapies to market, the resulting innovation will likely drive substantial revenue growth, fostering a competitive and dynamic Global Transthyretin Amyloidosis Treatment Market. In essence, the convergence of targeted therapies and RNA interference technologies marks a transformative phase, shaping the future of transthyretin amyloidosis treatment on a global scale.

Segmental Insights

Disease Type Insights

Based on the Disease Type, the Hereditary transthyretin amyloidosis segment is anticipated to witness substantial market growth throughout the forecast period. The Global Transthyretin Amyloidosis Treatment Market is poised for significant growth, driven by the prevalence and recognition of hereditary transthyretin amyloidosis (hATTR). As genetic testing and diagnostic capabilities advance, there is a heightened awareness of hATTR, contributing to an expanding patient pool seeking treatment interventions. The distinct genetic basis of hATTR not only underscores the need for specialized therapies but also propels research and development efforts to address the unique challenges posed by hereditary forms of the disease. Pharmaceutical companies, recognizing the specific demands of hATTR, are investing in targeted therapeutic solutions tailored to the genetic underpinnings of the condition. This strategic focus on hereditary transthyretin amyloidosis not only ensures more effective treatments but also positions companies competitively in an evolving market landscape. Moreover, the genetic heritability of the disease emphasizes the importance of early intervention and proactive management, creating a sustained demand for treatment options. The growing prevalence of hATTR, coupled with advancements in genetic medicine, establishes a fertile ground for the expansion of the Global Transthyretin Amyloidosis Treatment Market, signaling a transformative era in addressing the hereditary aspects of this complex medical condition.

Distribution Channel Insights

Based on the Distribution Channel segment, the Hospital Pharmacies segment has been the dominant force in the market. The growth of the Global Transthyretin Amyloidosis Treatment Market is intricately linked to the pivotal role played by hospital pharmacies. As frontline healthcare providers, hospital pharmacies serve as crucial distribution hubs for specialized transthyretin amyloidosis treatments. The increasing prevalence of the condition, coupled with the demand for timely and effective interventions, positions hospital pharmacies as key contributors to market expansion. Hospital pharmacies play a central role in the continuum of care, ensuring the availability and accessibility of transthyretin amyloidosis treatments to patients within the healthcare facility. Their strategic location within hospitals streamlines the prescription fulfillment process, facilitating efficient and coordinated patient care. Moreover, hospital pharmacies often collaborate closely with healthcare professionals, enabling them to provide valuable insights into treatment options and patient adherence. This collaboration fosters a seamless integration of transthyretin amyloidosis therapies into comprehensive patient care plans. The growing reliance on hospital pharmacies as central points for medication dispensing, information dissemination, and patient support positions them as critical drivers for the sustained growth of the Global Transthyretin Amyloidosis Treatment Market. Their role in enhancing treatment accessibility and fostering a cohesive healthcare ecosystem underscores their significance in shaping the future landscape of transthyretin amyloidosis management.


Download Sample Report

Regional Insights

North America, specifically the Transthyretin Amyloidosis Treatment Market, dominated the market in 2022, primarily due to North America is poised to be a key driver of the growth in the Global Transthyretin Amyloidosis Treatment Market. The region's robust healthcare infrastructure, coupled with a high prevalence of transthyretin amyloidosis cases, positions it as a major hub for treatment advancements and market expansion. The availability of advanced diagnostic technologies and a well-established healthcare ecosystem facilitates early detection, fostering a proactive approach to managing the disease. Pharmaceutical companies in North America are at the forefront of research and development initiatives, investing in innovative therapies tailored to address the specific needs of the diverse patient population affected by transthyretin amyloidosis. The region's regulatory environment and supportive healthcare policies further expedite the approval and commercialization of novel treatments, driving market growth. Additionally, the strong presence of academic and research institutions in North America fosters collaborations that contribute to the development of cutting-edge therapeutic solutions. The region's economic prosperity and high healthcare expenditure contribute to the affordability and accessibility of transthyretin amyloidosis treatments, further fueling market expansion.

Recent Developments

  • In January 2022, AstraZeneca’s drug Eplontersen received Orphan Drug Designation in the U.S. by the FDA for the transthyretin-mediated amyloidosis treatment.
  • In June 2022, Alnylam Pharmaceuticals, Inc. received FDA authorization for AMVUTTRA (vutrisiran) for the treatment of Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis.

Key Market Players

  • Pfizer Inc.
  • Johnson & Johnson Services Inc.
  • Ionis Pharmaceuticals Inc.
  • Alnylam Pharmaceuticals Inc.
  • BridgeBio Pharma Inc.
  • Bristol-Myers Squibb Company.
  • Acrotech Biopharma.
  • AstraZeneca Plc.
  • SOM Biotech.

 

 By Type

By Therapy

By Disease Type

By Distribution Channel

By Region
  • ATTR-PN
  • ATTR-CM
  • Targeted Therapy (Onpattro, Inotersen, Vyndaqel/Vyndamax)
  • Supportive Therapy
  • Pipeline Therapy
  • Hereditary Transthyretin Amyloidosis (Polyneuropathy, Cardiomyopathy, Mixed Type)
  • Wild Type Amyloidosis
  • Hospital Pharmacies
  • Specialty Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • North America
  • Europe
  • Asia Pacific
  • South America
  • Middle East & Africa

 

Report Scope:

In this report, the Global Transthyretin Amyloidosis Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

·         Transthyretin Amyloidosis Treatment Market, By Type:

o   ATTR-PN

o   ATTR-CM

·         Transthyretin Amyloidosis Treatment Market, By Therapy:

o   Targeted Therapy (Onpattro, Inotersen, Vyndaqel/Vyndamax)

o   Supportive Therapy

o   Pipeline Therapy

·         Transthyretin Amyloidosis Treatment Market, By Disease Type:

o   Hereditary Transthyretin Amyloidosis (Polyneuropathy, Cardiomyopathy, Mixed Type)

o   Wild Type Amyloidosis

·         Transthyretin Amyloidosis Treatment Market, By Distribution Channel:

o   Hospital Pharmacies

o   Specialty Pharmacies

o   Retail Pharmacies

o   Online Pharmacies

·         Transthyretin Amyloidosis Treatment Market, By Region:

    • North America

§  United States

§  Canada

§  Mexico

    • Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

    • Asia-Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

    • South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE


Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Transthyretin Amyloidosis Treatment Market.

Available Customizations:

Global Transthyretin Amyloidosis Treatment market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

·         Detailed analysis and profiling of additional market players (up to five).

Global Transthyretin Amyloidosis Treatment Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1.    Product Overview

1.1.  Market Definition

1.2.  Scope of the Market

1.2.1.       Markets Covered

1.2.2.       Years Considered for Study

1.2.3.       Key Market Segmentations

2.    Research Methodology

2.1.  Objective of the Study

2.2.  Baseline Methodology

2.3.  Key Industry Partners

2.4.  Major Association and Secondary Sources

2.5.  Forecasting Methodology

2.6.  Data Triangulation & Validation

2.7.  Assumptions and Limitations

3.    Executive Summary

3.1.  Overview of the Market

3.2.  Overview of Key Market Segmentations

3.3.  Overview of Key Market Players

3.4.  Overview of Key Regions/Countries

3.5.  Overview of Market Drivers, Challenges, Trends

4.    Voice of Customer

5.    Global Transthyretin Amyloidosis Treatment Market Outlook

5.1.  Market Size & Forecast

5.1.1.       By Value

5.2.  Market Share & Forecast

5.2.1.       By Type (ATTR-PN, ATTR-CM)

5.2.2.       By Therapy (Targeted Therapy (Onpattro, Inotersen, Vyndaqel/Vyndamax), Supportive Therapy, Pipeline Therapy)

5.2.3.       By Disease Type (Hereditary Transthyretin Amyloidosis (Polyneuropathy, Cardiomyopathy, Mixed Type), Wild Type Amyloidosis)

5.2.4.        By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, Online Pharmacies)  

5.2.5.       By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)

5.2.6.       By Company (2022)

5.3.  Market Map

5.3.1 By Type

5.3.2 By Therapy

5.3.3 By Disease Type

5.3.4 By Distribution Channel

5.3.5 By Region

6.    North America Transthyretin Amyloidosis Treatment Market Outlook

6.1.  Market Size & Forecast       

6.1.1.       By Value

6.2.  Market Share & Forecast

6.2.1.       By Type (ATTR-PN, ATTR-CM)

6.2.2.       By Therapy (Targeted Therapy (Onpattro, Inotersen, Vyndaqel/Vyndamax), Supportive Therapy, Pipeline Therapy)

6.2.3.       By Disease Type (Hereditary Transthyretin Amyloidosis (Polyneuropathy, Cardiomyopathy, Mixed Type), Wild Type Amyloidosis)

6.2.4.        By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, Online Pharmacies)  

6.2.5.       By Country

6.3.  North America: Country Analysis

6.3.1.       United States Transthyretin Amyloidosis Treatment Market Outlook

6.3.1.1.        Market Size & Forecast

6.3.1.1.1.           By Value

6.3.1.2.        Market Share & Forecast

6.3.1.2.1.           By Type

6.3.1.2.2.           By Therapy

6.3.1.2.3.           By Disease Type

6.3.1.2.4.           By Distribution Channel

6.3.2.       Canada Transthyretin Amyloidosis Treatment Market Outlook

6.3.2.1.        Market Size & Forecast

6.3.2.1.1.           By Value

6.3.2.2.        Market Share & Forecast

6.3.2.2.1.           By Type

6.3.2.2.2.           By Therapy

6.3.2.2.3.           By Disease Type

6.3.2.2.4.           By Distribution Channel

6.3.3.       Mexico Transthyretin Amyloidosis Treatment Market Outlook

6.3.3.1.        Market Size & Forecast

6.3.3.1.1.           By Value

6.3.3.2.        Market Share & Forecast

6.3.3.2.1.           By Type

6.3.3.2.2.           By Therapy

6.3.3.2.3.           By Disease Type

6.3.3.2.4.           By Distribution Channel

7.    Europe Transthyretin Amyloidosis Treatment Market Outlook

7.1.  Market Size & Forecast       

7.1.1.       By Value

7.2.  Market Share & Forecast

7.2.1.       By Type (ATTR-PN, ATTR-CM)

7.2.2.       By Therapy (Targeted Therapy (Onpattro, Inotersen, Vyndaqel/Vyndamax), Supportive Therapy, Pipeline Therapy)

7.2.3.       By Disease Type (Hereditary Transthyretin Amyloidosis (Polyneuropathy, Cardiomyopathy, Mixed Type), Wild Type Amyloidosis)

7.2.4.        By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, Online Pharmacies)  

7.2.5.       By Country

7.3.  Europe: Country Analysis

7.3.1.       France Transthyretin Amyloidosis Treatment Market Outlook

7.3.1.1.        Market Size & Forecast

7.3.1.1.1.           By Value

7.3.1.2.        Market Share & Forecast

7.3.1.2.1.           By Type

7.3.1.2.2.           By Therapy

7.3.1.2.3.           By Disease Type

7.3.1.2.4.           By Distribution Channel

7.3.2.       Germany Transthyretin Amyloidosis Treatment Market Outlook

7.3.2.1.        Market Size & Forecast

7.3.2.1.1.           By Value

7.3.2.2.        Market Share & Forecast

7.3.2.2.1.           By Type

7.3.2.2.2.           By Therapy

7.3.2.2.3.           By Disease Type

7.3.2.2.4.           By Distribution Channel

7.3.3.       United Kingdom Transthyretin Amyloidosis Treatment Market Outlook

7.3.3.1.        Market Size & Forecast

7.3.3.1.1.           By Value

7.3.3.2.        Market Share & Forecast

7.3.3.2.1.           By Type

7.3.3.2.2.           By Therapy

7.3.3.2.3.           By Disease Type

7.3.3.2.4.           By Distribution Channel

7.3.4.       Italy Transthyretin Amyloidosis Treatment Market Outlook

7.3.4.1.        Market Size & Forecast

7.3.4.1.1.           By Value

7.3.4.2.        Market Share & Forecast

7.3.4.2.1.           By Type

7.3.4.2.2.           By Therapy

7.3.4.2.3.           By Disease Type

7.3.4.2.4.           By Distribution Channel

7.3.5.       Spain Transthyretin Amyloidosis Treatment Market Outlook

7.3.5.1.        Market Size & Forecast

7.3.5.1.1.           By Value

7.3.5.2.        Market Share & Forecast

7.3.5.2.1.           By Type

7.3.5.2.2.           By Therapy

7.3.5.2.3.           By Disease Type

7.3.5.2.4.           By Distribution Channel

8.    Asia-Pacific Transthyretin Amyloidosis Treatment Market Outlook

8.1.  Market Size & Forecast       

8.1.1.       By Value

8.2.  Market Share & Forecast

8.2.1.       By Type (ATTR-PN, ATTR-CM)

8.2.2.       By Therapy (Targeted Therapy (Onpattro, Inotersen, Vyndaqel/Vyndamax), Supportive Therapy, Pipeline Therapy)

8.2.3.       By Disease Type (Hereditary Transthyretin Amyloidosis (Polyneuropathy, Cardiomyopathy, Mixed Type), Wild Type Amyloidosis)

8.2.4.        By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, Online Pharmacies)  

8.2.5.       By Country

8.3.  Asia-Pacific: Country Analysis

8.3.1.       China Transthyretin Amyloidosis Treatment Market Outlook

8.3.1.1.        Market Size & Forecast

8.3.1.1.1.           By Value

8.3.1.2.        Market Share & Forecast

8.3.1.2.1.           By Type

8.3.1.2.2.           By Therapy

8.3.1.2.3.           By Disease Type

8.3.1.2.4.           By Distribution Channel

8.3.2.       India Transthyretin Amyloidosis Treatment Market Outlook

8.3.2.1.        Market Size & Forecast

8.3.2.1.1.           By Value

8.3.2.2.        Market Share & Forecast

8.3.2.2.1.           By Type

8.3.2.2.2.           By Therapy

8.3.2.2.3.           By Disease Type

8.3.2.2.4.           By Distribution Channel

8.3.3.       Japan Transthyretin Amyloidosis Treatment Market Outlook

8.3.3.1.        Market Size & Forecast

8.3.3.1.1.           By Value

8.3.3.2.        Market Share & Forecast

8.3.3.2.1.           By Type

8.3.3.2.2.           By Therapy

8.3.3.2.3.           By Disease Type

8.3.3.2.4.           By Distribution Channel

8.3.4.       South Korea Transthyretin Amyloidosis Treatment Market Outlook

8.3.4.1.        Market Size & Forecast

8.3.4.1.1.           By Value

8.3.4.2.        Market Share & Forecast

8.3.4.2.1.           By Type

8.3.4.2.2.           By Therapy

8.3.4.2.3.           By Disease Type

8.3.4.2.4.           By Distribution Channel

8.3.5.       Australia Transthyretin Amyloidosis Treatment Market Outlook

8.3.5.1.        Market Size & Forecast

8.3.5.1.1.           By Value

8.3.5.2.        Market Share & Forecast

8.3.5.2.1.           By Type

8.3.5.2.2.           By Therapy

8.3.5.2.3.           By Disease Type

8.3.5.2.4.           By Distribution Channel

9.    South America Transthyretin Amyloidosis Treatment Market Outlook

9.1.  Market Size & Forecast       

9.1.1.       By Value

9.2.  Market Share & Forecast

9.2.1.       By Type (ATTR-PN, ATTR-CM)

9.2.2.       By Therapy (Targeted Therapy (Onpattro, Inotersen, Vyndaqel/Vyndamax), Supportive Therapy, Pipeline Therapy)

9.2.3.       By Disease Type (Hereditary Transthyretin Amyloidosis (Polyneuropathy, Cardiomyopathy, Mixed Type), Wild Type Amyloidosis)

9.2.4.        By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, Online Pharmacies)  

9.2.5.       By Country

9.3.  South America: Country Analysis

9.3.1.       Brazil Transthyretin Amyloidosis Treatment Market Outlook

9.3.1.1.        Market Size & Forecast

9.3.1.1.1.           By Value

9.3.1.2.        Market Share & Forecast

9.3.1.2.1.           By Type

9.3.1.2.2.           By Therapy

9.3.1.2.3.           By Disease Type

9.3.1.2.4.           By Distribution Channel

9.3.2.       Argentina Transthyretin Amyloidosis Treatment Market Outlook

9.3.2.1.        Market Size & Forecast

9.3.2.1.1.           By Value

9.3.2.2.        Market Share & Forecast

9.3.2.2.1.           By Type

9.3.2.2.2.           By Therapy

9.3.2.2.3.           By Disease Type

9.3.2.2.4.           By Distribution Channel

9.3.3.       Colombia Transthyretin Amyloidosis Treatment Market Outlook

9.3.3.1.        Market Size & Forecast

9.3.3.1.1.           By Value

9.3.3.2.        Market Share & Forecast

9.3.3.2.1.           By Type

9.3.3.2.2.           By Therapy

9.3.3.2.3.           By Disease Type

9.3.3.2.4.           By Distribution Channel

10. Middle East and Africa Transthyretin Amyloidosis Treatment Market Outlook

10.1.             Market Size & Forecast        

10.1.1.     By Value

10.2.             Market Share & Forecast

10.2.1.     By Type (ATTR-PN, ATTR-CM)

10.2.2.     By Therapy (Targeted Therapy (Onpattro, Inotersen, Vyndaqel/Vyndamax), Supportive Therapy, Pipeline Therapy)

10.2.3.     By Disease Type (Hereditary Transthyretin Amyloidosis (Polyneuropathy, Cardiomyopathy, Mixed Type), Wild Type Amyloidosis)

10.2.4.      By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, Online Pharmacies)  

10.2.5.     By Country

10.3.             MEA: Country Analysis

10.3.1.     South Africa Transthyretin Amyloidosis Treatment Market Outlook

10.3.1.1.     Market Size & Forecast

10.3.1.1.1.         By Value

10.3.1.2.     Market Share & Forecast

10.3.1.2.1.         By Type

10.3.1.2.2.         By Therapy

10.3.1.2.3.         By Disease Type

10.3.1.2.4.         By Distribution Channel

10.3.2.     Saudi Arabia Transthyretin Amyloidosis Treatment Market Outlook

10.3.2.1.     Market Size & Forecast

10.3.2.1.1.         By Value

10.3.2.2.     Market Share & Forecast

10.3.2.2.1.         By Type

10.3.2.2.2.         By Therapy

10.3.2.2.3.         By Disease Type

10.3.2.2.4.         By Distribution Channel

10.3.3.     UAE Transthyretin Amyloidosis Treatment Market Outlook

10.3.3.1.     Market Size & Forecast

10.3.3.1.1.         By Value

10.3.3.2.     Market Share & Forecast

10.3.3.2.1.         By Type

10.3.3.2.2.         By Therapy

10.3.3.2.3.         By Disease Type

10.3.3.2.4.         By Distribution Channel

11. Market Dynamics

11.1.             Drivers

11.2.             Challenges

12. Market Trends & Developments

12.1.             Recent Development

12.2.             Mergers & Acquisitions

12.3.             Product Launches

13. Global Transthyretin Amyloidosis Treatment Market: SWOT Analysis

14. Porter’s Five Forces Analysis

14.1.             Competition in the Industry

14.2.             Potential of New Entrants

14.3.             Power of Suppliers

14.4.             Power of Customers

14.5.             Threat of Substitute Products

15. Competitive Landscape

15.1.             Pfizer Inc.

15.1.1.     Business Overview

15.1.2.     Product Offerings

15.1.3.     Recent Developments

15.1.4.     Financials (As Reported)

15.1.5.     Key Personnel

15.1.6.     SWOT Analysis

15.2.             Johnson & Johnson Services Inc.

15.3.             Ionis Pharmaceuticals Inc.

15.4.             Alnylam Pharmaceuticals Inc.

15.5.             BridgeBio Pharma Inc.

15.6.             Bristol-Myers Squibb Company.

15.7.             Acrotech Biopharma.

15.8.             AstraZeneca Plc.

15.9.             SOM Biotech.

16. Strategic Recommendations

Figures and Tables

Frequently asked questions

down-arrow

The market size of the Global Transthyretin Amyloidosis Treatment Market was estimated to be USD 4.95 Billion in 2022.

down-arrow

The Hereditary transthyretin amyloidosis segment demonstrated significant dominance in 2022, primarily due to Hereditary transthyretin-mediated amyloidosis is an autosomal dominant, rare, and fatal disease in which it impairs multiple organs, leading to death and disability.

down-arrow

North America emerged as the dominant market in 2022, Increasing novel drugs prescription, proper reimbursement policies, and higher treatment rates in the region.

down-arrow

Extensive research in the development of new therapies and the presence of robust pipeline drugs that are used to treat transthyretin will propel Global Transthyretin Amyloidosis Treatment market growth during the forecast period.

Related Reports

profile

Sakshi Bajaal

Business Consultant
Press Release

Transthyretin Amyloidosis Treatment Market to Grow with a CAGR of 7.26% through 2028

Nov, 2023

Increasing prevalence of transthyretin amyloidosis are expected to drive the Global Transthyretin Amyloidosis Treatment Market growth in the forecast period, 2024-2028.

Why Choose Us